Lack of flu causes Hypera to fail

Currently, Hypera’s performance is slightly lower than market expectations, and the stock price is expected to fall by nearly 8%.

One company achieves fracking growth sold out Growth in the third quarter was only 4.2% year-on-year, a decline market share. (The pharmaceutical market grew by 8.8% during the same period).

The slowdown in sales is largely due to a more severe flu season, with case numbers falling about 30% each quarter. Since anti-influenza drugs are highly represented during this period (37%), their impact on Hypera is relevant.

Part of the question is based on comparison.

The third quarter of last year was still marked by a return to normal life rather than a post-Covid era, as doctors prescribed a basket of drugs at the first sign of “atchim!” This helped with bandages last year, but with the Covid-19 pandemic failing this year, that effect has now disappeared.

The results were even worse because the company managed to make up for the delay by increasing sales of its skin care products in the institutional market—a market that is still small for the company but is growing rapidly.

There was no quarter in which the institutional market contributed R$119 million in revenue. The company estimates that this vertical will generate revenue of 400 million reais this year and may reach 1.4 billion reais in the next few years.

According to analysts today, the company said that around 2% of its consolidated growth should be seen in the market over the next few years.

Chief executive Breno de Oliveira also said anti-flu products were not highly represented in sales in the fourth and first quarters of this year – typically around 20%. For the fourth quarter, we expect growth to be in line with or slightly above the market line.

Secondly, Hypera has not fallen into a price crisis for low-margin products, or may have resulted in negative profits on some products. “Our focus is on profitability and cash management rather than earning share for the sake of earning share,” he said.

One analyst said we need to pay attention to the fact that Hypera isn’t trying to turbocharge her. sell To end the quarter, the previous management’s long-standing document – despite being its least successful quarter, the company continued to post very solid operating and financial metrics.

Hypera fez has quarterly revenue of R$2.1 billion, EBITDA of R$774,000, and net profit of R$470,000.

Leaving the company results in a 5% reduction in value guide Annual Revenue, EBITDA and Profit.

Along with the price cut, Bradesco BBI downgraded its paper rating, changing the recommendation from “buy” to “neutral” and lowering the price from 51 reais to 44 reais.

Currently trading at just over 31 reais.

Analysts at Bradesco said the rating would be downgraded after incorporating the model or new guidance, which would mean EBITDA in the third quarter was 17% lower than the bank’s forecast.

“As a result, we lower our profit forecast for this year from 10% to 1.9 billion reais, 12% below consensus,” the bank said.

The company’s next challenge will be the possibility of withdrawing its own capital commitments, referring to the company’s preferential way of distributing profits to shareholders, and treating DRE as a deductible allowance, thereby reducing taxes.

In a bizarre twist, two analysts paid by the company issued reports saying the results were not “in line with expectations.”

However, it only needs to be combined with the market itself, which has accumulated notes since the opening, and its trading volume is more than five times the average daily trading volume.

Source link

Leave a Comment